Founded in Berkeley, California, Acrigen Biosciences is an early-stage life science company dedicated to revolutionizing medicine through precision gene-editing technology. Their core mission is to develop therapies for genetic disorders using their proprietary CRISPR-based systems. Acrigen's innovative approach leverages novel αCas and μCas CRISPR gene editors, along with engineered anti-CRISPR proteins (ErAcrs), to create a highly efficient and precise gene-editing toolbox. The company aims to bring hope to millions of patients suffering from genetic diseases by harnessing the power of these advanced technologies.

Acrigen Biosciences has attracted attention from notable figures in the biotechnology and medical research fields, as well as securing investments from leading venture capital firms specializing in life sciences. The company's key achievements include the development of their proprietary gene-editing systems, which have demonstrated best-in-class efficiency and precision in preclinical studies. Acrigen's impact lies in its potential to transform the treatment landscape for genetic disorders, offering new therapeutic options that could significantly improve patient outcomes.